WEST HARRISON, NY, United States, via ETELIGIS INC., 02/27/2015 – – CEL-SCI Corporation (NYSE MKT: CVM), arguably the most undervalued Phase III biotech, is featured in the February 24th issue of Flaherty Special Situation Newsletter. Upcoming is a possible settlement of its $50 million arbitration suit against CEL-SCI’s former clinical research organization for breach of contract and fraud with a scheduled May 4th trial start with a possible final judgment including hundreds of millions in punitive damages.
This turnaround aims to enroll 880 head and neck cancer patients in over 100 sites in at least 21 countries before yearend. Success in this global Phase III trial of its lead immunotherapy drug regime Multikine could be rewarded with a one day stock jump of billions. Other tantalizing possibilities exist for Human Papilloma Virus and rheumatoid arthritis. Dreamer Geert Kersten and his outstanding team are building a keeper.
Our complete in depth sponsored CEL-SCI Corporation Buy report can be found archived on our Flaherty Financial News website at http://www.flahertyfinancialnews.com/ .
Direct Server Link to The Report – With The Modern Social Share Buttons:
About Flaherty Financial News Inc.
Flaherty Financial News Inc. ("FFN") is the publisher of totally-electronic coverage of interesting public companies. FFN was launched in 2007 by the "legendary financial editor" Bob Flaherty, Editor and Chairman of Flaherty Financial News Inc., and his son Brian, President and Publisher. While previously serving as Chairman and Editor of Equities Magazine for twenty-five years and also Editor-in-Chief of Equities Special Situations, Bob had one of the most consistent and highest ranked long-run performance records measured by Hulbert Financial Digest. He is also an award-winning retired Senior Editor of Forbes Magazine, where he wrote 33 cover stories, two shy of the all-time Forbes record. He was also Chairman of The Over-The-Counter Securities Fund. Bob Flaherty is a Magna Cum Laude graduate of Harvard College in economics and also has an MBA with a Distinction in Finance from Harvard Business School. A former president of the New York Financial Writers’ Association, Bob is a co-founder of their annual student scholarship program and their annual award for significant long-term achievement in financial journalism.
About CEL-SCI Corporation.
CEL-SCI’s work is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. Its lead investigational immunotherapy Multikine (Leukocyte Interleukin, injection) is currently being studied in a pivotal Phase III clinical trial against head and neck cancer. If the study endpoint, which is a 10% improvement in overall survival of the subjects treated with Multikine treatment regimen as compare to subjects treated with current standard of care only is satisfied, the study results will be used to support applications which will be submitted to regulatory agencies in order to receive from these agencies commercial marketing approvals for Multikine in major markets around the world. Additional clinical indications for Multkkine which are being investigated include cervical dysplasia in HIV/HPV co-infected women, and the treatment of peri-anal warts in HIV/HPV co-infected men and women. A Phase I trial of the former indication has been completed at the University of Maryland. The latter indication is now a Phase I trial in conjunction with U.S. Navy under a CRADA (Cooperative Research and Development Agreement).
CEL-SCI is also developing its LEAPS technology for the treatment of pandemic influenza and as a potential vaccine against rheumatoid arthritis. The Company has recently received a Phase I SBIR Grant from the National Institutes of Health to develop LEAPS as a potential treatment for rheumatoid arthritis with researchers from Rush University Medical Center in Chicago, IL. The Company has operations in Vienna, VA and in and near Baltimore, MD.
This news release contains “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of l995) regarding the special situation report on CEL-SCI Corporation and its future business plans. These statements involve known and unknown risks and uncertainties, which may cause actual results and future achievements to be materially different than those implied by these forward-looking statements. Flaherty Financial News Inc. and CEL-SCI Corporation have and undertake no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in their expectations of future events. Our full disclaimer and safe harbor statement appears in our special situation newsletter.
Flaherty Financial News Inc.
Robert J. Flaherty, Editor and Chairman
Phone: (914) 831-1151
Gavin de Windt, Investor Relations
Phone: (703) 506-9460
SOURCE: Flaherty Financial News Inc.